Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …

Mutational profiling has demonstrated utility in predicting the likelihood of disease
progression in patients with myelofibrosis (MF). However, there is limited data regarding the …

Myelofibrosis is a rare hematologic malignancy with limited curative therapeutic options.
Significant advances in our understanding of disease pathogenesis have led to new targets …

Myelofibrosis (MF) is a clonal stem cell neoplasm with heterogeneous clinical phenotypes
and well‐established molecular drivers. Allogeneic haematopoietic stem cell transplantation …

Background Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the
only curative treatment for patients with myelofibrosis (MF). Transplant related mortality …

Opinion statement Myelofibrosis (MF) is a clonal disorder of the pluripotent hematopoietic
stem cell, whose clinical manifestations can be extremely heterogeneous, including …

Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary
hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in …

Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …

Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …

Hematopoietic cell transplantation (HCT) provides potentially curative treatment for patients
with myelofibrosis (MF). HCT outcomes are associated with the Dynamic International …